Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCABNASDAQ:BCELNASDAQ:CINGNASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.38+2.4%$0.43$0.24▼$2.53$22.43M0.92922,392 shs379,590 shsBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/ACINGCingulate$4.05-1.2%$4.11$1.80▼$20.83$17.20M-0.851.11 million shs45,701 shsMIRAMIRA Pharmaceuticals$1.25+2.9%$1.22$0.51▼$5.01$21.07M1.962.21 million shs76,588 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%-4.33%-1.79%+2.87%-72.77%BCELAtreca0.00%0.00%0.00%0.00%0.00%CINGCingulate0.00%-2.17%+1.50%-6.90%+618.09%MIRAMIRA Pharmaceuticals0.00%+2.05%-7.09%+17.45%+76.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.7054 of 5 stars3.32.00.00.03.32.50.6BCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate3.1286 of 5 stars3.54.00.00.03.60.80.6MIRAMIRA Pharmaceuticals2.9249 of 5 stars3.75.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,202.08% UpsideBCELAtreca 0.00N/AN/AN/ACINGCingulate 3.00Buy$26.00541.98% UpsideMIRAMIRA Pharmaceuticals 3.33Buy$14.001,024.50% UpsideCurrent Analyst Ratings BreakdownLatest BCEL, CING, BCAB, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.003/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.04N/AN/A$0.25 per share1.54BCELAtrecaN/AN/AN/AN/A$2.01 per shareN/ACINGCingulateN/AN/AN/AN/A$2.32 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)BCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/ACINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)Latest BCEL, CING, BCAB, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35BCELAtrecaN/A1.581.58CINGCingulate0.161.871.87MIRAMIRA PharmaceuticalsN/A12.8612.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%BCELAtreca37.47%CINGCingulate41.31%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%BCELAtreca11.30%CINGCingulate5.27%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableBCELAtreca13039.62 million35.15 millionOptionableCINGCingulate204.25 million4.02 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionableBCEL, CING, BCAB, and MIRA HeadlinesRecent News About These CompaniesMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - El Paso TimesJune 26 at 7:37 PM | elpasotimes.comEMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Des Moines RegisterJune 26 at 7:37 PM | desmoinesregister.comDMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - The Columbus DispatchJune 26 at 7:37 PM | dispatch.comMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Milwaukee Journal SentinelJune 26 at 7:37 PM | jsonline.comJMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - Courier-JournalJune 26 at 7:37 PM | courier-journal.comCMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - azcentral.comJune 26 at 7:37 PM | azcentral.comAMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking ... - Asbury Park PressJune 26 at 7:37 PM | app.comAMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - The Journal News or lohud.comJune 26 at 7:37 PM | lohud.comLMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without ...June 26 at 12:11 PM | finanznachrichten.deMIRA Announces Positive Test Results from AcquisitionJune 26 at 2:42 AM | finance.yahoo.comMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 – A Drug Candidate Pending Acquisition – To Disrupt Weight Loss and Smoking Cessation Markets ...June 25, 2025 | tennessean.comTMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side EffectsJune 25, 2025 | accessnewswire.comAMIRA Gets Validation from JournalJune 18, 2025 | finance.yahoo.comMIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in PharmacologyJune 18, 2025 | accessnewswire.comAMIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology JournalJune 17, 2025 | tipranks.comVisionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS PlatformJune 5, 2025 | thenewswire.comTMIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical ProgramMay 28, 2025 | accessnewswire.comAMIRA Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comMIRA Releases Financials as Research ContinuesMay 15, 2025 | finance.yahoo.comMIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60MMay 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeArcher's Midnight Air Taxi Soars, But Stock Doesn’t BudgeBy Jeffrey Neal Johnson | June 4, 2025View Archer's Midnight Air Taxi Soars, But Stock Doesn’t BudgeHims & Hers Stock: Buy the Dip or Wait It Out?By Gabriel Osorio-Mazilli | June 5, 2025View Hims & Hers Stock: Buy the Dip or Wait It Out?Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?By Jeffrey Neal Johnson | June 8, 2025View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?Is Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say YesBCEL, CING, BCAB, and MIRA Company DescriptionsBioAtla NASDAQ:BCAB$0.38 +0.01 (+2.37%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.40 +0.02 (+4.17%) As of 06/27/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Atreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Cingulate NASDAQ:CING$4.05 -0.05 (-1.22%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$4.06 +0.00 (+0.12%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.MIRA Pharmaceuticals NASDAQ:MIRA$1.25 +0.04 (+2.89%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.72%) As of 06/27/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
